证券代码：002019 证券简称：亿帆医药 亿帆医药股份有限公司投资者关系活动记录表 | --- | |----------------| | | | 投资者关系活动 | | 类别 | | | | | | | | | | | | | | | | | | | | | | | | | | 活动参与人员 | | | | | | | | | | | | | | | | | | | | | | --- | |--------------------------------------------------------------| | 云；承珞资本：林田心；睿郡资产：魏志华；朴石投资：段越；尚 | | 石资本：贾鹏飞；鹤禧基金：吴迪龙；上海国鸣投资：张同鑫；问 | | 渠私募：胡德军；天弋投资：章轶；上海丰煜投资：文彧；上海聚 | | 宜投资：王坚；上海虹诗投资：王慧超；上海博亚：徐辉；联君资 | | 管：程建华；鹏扬基金：王雪刚；恒立基金：马犇；永唐盛世资管： | | 杜之鹏；上海名禹资管：王友红；鲸诚资产：万巍；泰霖投资：吕 | | 周延；盛熙基金：竺吉锋；易鑫安资管：于昕可；崇山投资：欧阳 | | 亦轩；昶元投 ...

Financial Performance - The net profit attributable to shareholders decreased by 21.93% after excluding non-recurring gains and losses[16] - Net profit attributable to shareholders of the listed company decreased by 46.59% to ¥64,774,428.20 from ¥121,266,909.58 year-on-year[38] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥59,978,038.28, down 21.93% from ¥76,821,416.28 in the previous year[38] - Basic and diluted earnings per share both decreased by 50.00% to ¥0.05 from ¥0.10 year-on-year[38] Revenue and Cash Flow - The total operating revenue for Q1 2023 was ¥938,532,039.13, representing a 3.60% increase compared to ¥905,920,591.79 in the same period last year[38] - The net cash flow from operating activities increased by 104.44% compared to the same period last year, mainly due to an increase in received payments[16] - The net cash flow generated from operating activities improved significantly to ¥2,042,875.34, compared to a negative cash flow of ¥46,018,343.12 in the same period last year, marking a 104.44% increase[38] - The company reported cash inflows from operating activities of CNY 1,077,790,038.41 in Q1 2023, an increase from CNY 1,007,886,294.93 in the same period last year, representing a growth of approximately 6.9%[58] - The company reported a decrease in cash outflows for operating activities, totaling CNY 1,075,747,163.07 in Q1 2023, compared to CNY 1,053,904,638.05 in Q1 2022, showing improved cash management[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,588,862,242.31, a slight increase of 0.36% from ¥12,543,503,416.06 at the end of the previous year[38] - The total current assets increased, with cash and cash equivalents reaching ¥1,214,966,438.53, up from ¥1,143,783,700.15[30] - The total liabilities increased to ¥3,423,082,919.34 from ¥3,397,259,755.63 year-on-year[38] - The company's financial assets decreased by 84.29% to 15,000,000.00 yuan, attributed to the redemption of financial products[40] Expenses and Impairments - Tax and additional charges increased by 54.14% to ¥10,831,847.60, primarily due to VAT and related taxes from inter-company transactions[8] - Other income decreased by 89.32% to ¥4,844,318.49, mainly due to a reduction in government subsidies received[8] - Operating costs rose to ¥480,751,477.19, compared to ¥427,472,846.50 in the same period last year[38] - The company recorded an asset impairment loss increase of 814.24% to ¥-1,221,138.65, mainly due to inventory impairment[19] - The company reported a significant reduction in credit impairment losses by 96.74% to ¥-124,882.34, attributed to the recovery of accounts receivable[8] Investments and Development - Investment income improved by 32.17%, with losses from joint ventures decreasing[8] - Research and development expenses for the period were ¥47,510,975.21, up from ¥38,302,629.24 in the previous year[33] - The company received several drug registration certificates, including for the injection of Sulfate Vincristine and other products, enhancing its product portfolio[25][28] - The company’s subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received a drug registration certificate for Lacosamide injection on March 10, 2023[48] - The company’s subsidiary, Yiyi Biopharmaceutical Development (Shanghai) Co., Ltd., received a clinical trial approval notice for the product F-652 on March 21, 2023[50] Financing Activities - Total cash inflow from financing activities was $1,112,952,122.70, compared to $814,866,505.67 in the prior period, reflecting a significant increase[78] - Cash outflow from financing activities amounted to $990,189,051.81, up from $460,883,663.95 in the previous year[78] - Net cash flow from financing activities was $122,763,070.89, a decrease from $353,982,841.72 year-over-year[78] - Cash received from borrowings was $1,112,216,128.41, an increase from $814,866,505.67 in the prior year[78] - Cash paid for debt repayment was $956,496,784.74, significantly higher than $436,316,371.62 in the previous period[78]

Financial Performance - The net profit attributable to shareholders decreased by 63.98% year-on-year, primarily due to an increase in government subsidies compared to the previous year[33]. - The net cash flow from operating activities increased by 56.71% year-on-year, mainly due to an increase in government subsidies received and tax refunds from national preferential policies[34]. - The company plans not to distribute cash dividends or bonus shares, nor to increase capital from reserves[16]. - The company reported a significant decline in pharmaceutical service revenue, leading to an increase in asset impairment provisions[33]. - The net profit attributable to shareholders in the fourth quarter significantly decreased compared to the previous three quarters due to the full impairment provision for R&D projects that could not meet expectations[37]. - The net profit excluding non-recurring gains and losses in the fourth quarter also saw a substantial decline, primarily due to government subsidies received during the quarter[37]. - Government subsidies recognized in the current period amounted to approximately ¥130.05 million, which is a key factor in the financial results[39]. - The total net profit after tax and minority interests for the fourth quarter was approximately ¥111.91 million, reflecting the impact of the aforementioned factors[39]. - The company’s operating revenue for 2022 was ¥3,836,640,799.74, a decrease of 12.98% compared to ¥4,409,035,585.85 in 2021[51]. - The net profit attributable to shareholders for 2022 was ¥191,277,350.92, down 31.29% from ¥278,398,951.02 in 2021[51]. - The net profit after deducting non-recurring gains and losses was ¥79,371,328.72, a decline of 63.98% compared to ¥220,375,153.57 in 2021[51]. - The net cash flow from operating activities increased by 56.71% to ¥472,065,141.66 in 2022, up from ¥301,231,402.96 in 2021[51]. - The total assets at the end of 2022 were ¥12,543,503,416.06, reflecting a 3.11% increase from ¥12,165,124,976.56 at the end of 2021[51]. - The net assets attributable to shareholders increased by 3.24% to ¥8,811,484,555.00 at the end of 2022, compared to ¥8,535,174,993.28 at the end of 2021[51]. - The company reported a basic earnings per share of ¥0.16 for 2022, down 30.43% from ¥0.23 in 2021[51]. - The weighted average return on equity for 2022 was 2.20%, a decrease of 1.08% from 3.28% in 2021[51]. Risk Management - The company has identified various risks in its operations, including R&D underperformance, goodwill impairment, exchange rate fluctuations, international business risks, and safety and environmental risks[5]. - The company has not experienced any substantial risks that could significantly impact its production and operations during the reporting period[5]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its future development statements[11]. Research and Development - The company is focusing on R&D projects, including the development of new products such as F-627 and F-652, which are currently under research[43]. - The company aims to leverage innovation to meet unmet clinical needs and enhance international competitiveness in the pharmaceutical sector[85]. - The company will adopt a cooperative and self-research approach for new product development, emphasizing innovation-driven strategies and green manufacturing initiatives[102]. - The company is committed to pursuing high-quality sustainable development by focusing on patient needs and avoiding homogenized competition in drug development[102]. - The company will focus on key traditional Chinese medicine products, enhancing development and academic construction to elevate product academic status and transition to mass branding[95]. - The company aims to strengthen its innovation capabilities in synthetic biology technology through collaboration with research institutions and self-built R&D teams, aligning with global trends[97]. - The company has improved its procurement system for core Chinese medicinal materials and key raw materials, ensuring optimal supplier performance in price, quality, and service[108]. - The company has established a complete independent system for R&D, procurement, production, and sales based on market demand and its actual situation[108]. - The company’s new product development is primarily based on independent R&D, supplemented by collaborations with overseas and domestic research institutions[112]. Market Position and Strategy - The company holds a leading position in the vitamin B5 market, with over 70% of its sales directed to Europe and the United States[69]. - The company plans to continue its market expansion and strategic acquisitions to enhance its competitive position in the pharmaceutical industry[43]. - The company is one of the few domestic firms to submit new drug applications for the same product simultaneously in the US, Europe, and China, indicating strong market positioning[88]. - The company has a high global market share in raw material drugs, with over 70% of Vitamin B5 products sold to Europe and the US, maintaining a leading position[88]. - The company’s sales strategy for the product Aibegesitin α injection mainly involves external authorization, receiving milestone payments and net sales royalties[110]. - The company’s core Chinese medicine products and key chemical drug products are produced based on market sales conditions and product demand plans[108]. Environmental Compliance - The company has established a comprehensive emergency response mechanism for environmental pollution incidents and has conducted multiple drills to enhance emergency handling capabilities[173]. - The company has achieved compliance in all monitored environmental discharge parameters, including wastewater and air emissions, with specific values such as 19.7 mg/L for biochemical oxygen demand and 8.5 mg/m³ for particulate matter[171]. - The company has implemented a "2022 Employee Stock Ownership Plan" to motivate and retain talent, alongside a comprehensive employee benefits system[177]. - The company has made significant investments in pollution control facilities, including a rotary kiln incinerator and a sludge dewatering machine, to ensure compliance with environmental regulations[171]. - The company has maintained transparency in information disclosure, enhancing communication with investors through various channels[176]. - The company has no recorded violations or penalties during the reporting period, indicating a strong compliance record[174]. - The company reported that it continues to meet environmental discharge standards for its operations[191]. - The company has established online monitoring systems for wastewater and air emissions, with data automatically uploaded to environmental authorities, ensuring compliance with national monitoring regulations[198]. - In 2022, all self-monitoring and supervisory monitoring results were compliant, demonstrating the company's effective pollution management capabilities[198]. - The company is actively conducting annual carbon emission audits to guide energy-saving measures across departments, aiming to reduce overall energy consumption[199]. Employee and Governance - The total number of employees is 4,338, with 1,092 in sales, 849 in technical roles, and 178 in finance[145]. - The company has implemented a training program for employees, focusing on various levels and roles to enhance skills and performance[146]. - The company’s governance structure includes various committees that have met multiple times to discuss performance evaluations and compensation plans[143]. - The company has a total of 36 employees with a PhD, 213 with a master's degree, and 1,278 with a bachelor's degree, indicating a strong educational background among staff[145]. - The employee stock ownership plan purchased a total of 7,292,100 shares, accounting for 0.59% of the company's total share capital, at an average price of RMB 10.765 per share, totaling approximately RMB 78.5 million[157]. - The company has implemented a dynamic management approach for its R&D projects, increasing investment in key products[138]. - The company plans to enhance its governance structure and internal control systems to improve operational compliance and investor relations[189].

现场参与地点：安徽省合肥市肥西县桃花镇繁华大道与文山路交口，合肥亿 帆生物制药有限公司一楼会议室。 亿帆医药股份有限公司（以下简称"公司"）于2023年4月15日在巨潮资讯 网上披露了《2022年年度报告》，为了让广大投资者更深入全面地了解公司经营 管理、发展战略、行业前景等情况，公司将举行2022年度业绩说明会，具体安排 如下： 一、说明会时间、地点和形式 股票代码：002019 股票简称：亿帆医药 公告编号：2023-030 亿帆医药股份有限公司 关于举行 2022 年度业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要事项提示： 会议时间：2023年6月2日（周五） 13:00-15:00 会议形式：现场参与+网络视频直播 欢迎广大投资者积极参与本次网上说明会。 （问题征集二维码） 召开时间：2023年6月2日（周五）13:00-15:00 召开形式：现场参与+网络视频直播 本次业绩说明会将采用"现场参与+网络视频直播"的方式实现线上线下同 步进行。线下会场设在安徽省合肥市肥西县桃花镇繁华大道与文山路交口，合肥 亿帆生物制药有限公司一 ...

Group 1: Company Overview - The company is Zhejiang Hangzhou Xinfuyuan Pharmaceutical Co., Ltd. with stock code 002019 [1] - The investor relations activity took place on November 6, 2014, in Hefei, Anhui Province [2] Group 2: Investor Relations Activity - The event was categorized as an investor reception day, attended by various securities analysts and fund representatives [2] - Key company representatives included the Chairman, General Manager, Deputy General Manager, CFO, and Secretary of the Board [2] Group 3: Policy and Market Impact - Discussion on the potential impact of the National Development and Reform Commission's proposed drug price management reforms on the company [2][3] - The company does not base its development strategy solely on pricing but aims to strengthen its foundation through product diversification and vertical and horizontal industry development [3] Group 4: Future Development Directions - Future focus will be on the integration of pharmaceutical raw materials and products, with potential expansion into the healthcare industry [3] - Plans for overseas product development include product agency, ownership buyouts, and acquisitions of foreign companies [3] Group 5: Market Trends - Current pricing of calcium pantothenate is at a relatively low level, with future price trends difficult to predict; the company will adapt to market conditions [3]

Group 1: Company Overview - Yifan Xinfu Pharmaceutical Co., Ltd. is actively engaging in investor relations activities to provide insights into its operations and strategic direction [1]. - The company is located in Hefei, Anhui Province, and the meeting took place on May 6, 2015 [1]. Group 2: Industry Position and Strategy - The company is focused on the healthcare industry, with ongoing efforts to adapt to national policies and explore effective collaboration models [2]. - Future development in the pharmaceutical sector is centered around innovation and targeted product acquisitions [2]. Group 3: Product Development and Pricing - Yifan Xinfu aims to strengthen its core business in the pantothenic acid series while also developing biodegradable materials [2]. - The recent price drop of pantothenic acid products is a strategic decision based on market conditions, with the company expressing a willingness to increase market share [2]. - The impact of drug price deregulation is expected to be minimal in the short term, but long-term effects may influence companies relying on individually priced products for profit [2].

Group 1: Price Trends and Market Conditions - The recent global market has seen an upward trend in the prices of vitamin products, including calcium pantothenate (vitamin B5), which was at a low price point in 2015 and is expected to rise [2] - The tightening of domestic environmental regulations may have led to some manufacturers being unable to fully release production capacity, resulting in a market characterized by tight supply and increased production costs [2] - The company anticipates that the price of calcium pantothenate will continue to rise in the future, although the duration and extent of the increase are uncertain and ultimately determined by market conditions [2] Group 2: Production and Capacity - The total production capacity for the company's pantothenic acid series products is 12,000 tons per year [2] - The company will decide on order placements based on market conditions and actual production situations, with prices generally following market trends [2] Group 3: Strategic Development - The company's future strategic focus includes three main areas: pharmaceutical raw materials, drug formulations, and the healthcare sector [2] - The company aims to enhance innovation and promote business integration and upgrading while achieving some success in internationalization through strategies like "going out" and "bringing in" [3] - In developing regions, the company plans to establish local factories to supply domestic products, while in developed regions like Europe and the U.S., it will pursue acquisitions of international pharmaceutical companies to expand its global market presence [3]

Group 1: Product Pricing and Market Trends - The price of calcium pantothenate is expected to rise due to a general upward trend in vitamin product prices globally [2] - In 2015, the price of vitamin B5 (calcium pantothenate) was at a low level, indicating potential for upward movement [2] - Strict domestic environmental regulations may have limited production capacity for some manufacturers, leading to a tight supply and increased production costs [2] - The company's total production capacity for pantothenic acid series products is 12,000 tons per year [2] Group 2: Biodegradable Materials - The company launched a fully biodegradable materials project in 2007, featuring proprietary technology and the first continuous production facility in China with a capacity of 10,000 tons [3] - The biodegradable products have gained recognition from customers in Europe and the United States, and the company is the drafting unit for national standards [3] - The products are primarily exported, but domestic demand is expected to grow as environmental regulations become stricter [3] Group 3: Healthcare Development Strategy - The company aims to establish a hospital management system in Anhui within 3-5 years, starting with the management of county-level hospitals [3] - The strategy includes building high-end hospitals and a national chain for specialized treatments, focusing on chronic disease management [3] - The company has initiated its healthcare business by partnering with top medical institutions in Anhui and successfully managing a county hospital [4] Group 4: Future Business Strategy - The company’s strategic focus post-restructuring includes pharmaceutical raw materials, drug formulations, and healthcare sectors [4] - Plans for domestic integration of product lines and international expansion through local manufacturing in underdeveloped regions and acquisitions in developed markets are outlined [4]

Group 1: Company Overview - Yifan Xinfu Pharmaceutical Co., Ltd. is involved in strategic cooperation with Jianenlong, focusing on innovation and international market strategies [2][3]. - The major shareholder remains unchanged post-transaction, indicating a financial investment completion [3]. Group 2: Core Competencies - Jianenlong's core competencies include advanced technology and a strong management team, with two major platforms for intellectual property protection [3]. - The company has established a cGMP-compliant industrialization factory according to FDA standards and is the first Chinese biotech firm to conduct Phase II clinical trials in the U.S. [3]. Group 3: Financial Insights - Jianenlong has invested over $80 million since its establishment and requires an additional $200 million in the next 2-3 years for future financing [4]. - The G-CSF project, originally developed by Amgen, is expected to generate a market share of $6 billion annually in Europe and the U.S., with long-acting products accounting for 80% of that market [4]. Group 4: Market Potential - The orphan drug project F-652 is projected to reach a market capacity of $1-1.2 billion, benefiting from shorter clinical timelines and faster approval processes [4].

Financial Performance - Revenue for Q3 2022 was ¥959,518,634.11, a decrease of 5.94% year-over-year, and a total revenue of ¥2,728,866,329.74 for the year-to-date, down 19.68% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2022 was ¥42,696,040.25, a decline of 45.00% year-over-year, with year-to-date net profit of ¥203,256,070.64, down 30.10%[3]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥24,925,435.23, a decrease of 62.08% year-over-year, and year-to-date was ¥130,283,488.50, down 47.89%[3]. - The company reported a significant decrease in pharmaceutical service revenue, which contributed to the decline in net profit[3]. - The company reported a net profit margin decline due to reduced operating revenue and increased costs, impacting overall profitability[22]. - The total revenue for Q3 2022 was approximately 753.19 million, an increase from 607.22 million in Q3 2021, representing a growth of about 24%[24]. - The net profit for Q3 2022 was approximately 150.26 million, down from 242.33 million in Q3 2021, indicating a decrease of about 38%[24]. - Operating profit for Q3 2022 was approximately 186.75 million, compared to 277.14 million in Q3 2021, reflecting a decline of about 33%[24]. - The basic earnings per share for Q3 2022 was 0.16, compared to 0.24 in Q3 2021, a decline of about 33%[25]. - The total comprehensive income attributable to the parent company's owners for Q3 2022 was approximately 196.35 million, compared to 204.24 million in Q3 2021, a decrease of about 4%[25]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥12,693,749,219.29, an increase of 4.35% from the end of the previous year[3]. - Total assets increased to approximately $12.69 billion, up from $12.17 billion year-over-year, reflecting a growth of about 4.3%[21]. - Total liabilities rose to approximately $3.57 billion, compared to $3.39 billion in the previous year, indicating an increase of about 5.5%[21]. - Non-current assets totaled approximately $8.77 billion, an increase from $8.58 billion, showing a growth of about 2.2%[21]. Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥273,207,235.15, a decrease of 16.68% compared to the previous year[3]. - Cash flow from operating activities for Q3 2022 was approximately 273.21 million, down from 327.90 million in Q3 2021, a decrease of about 17%[27]. - Cash flow from investment activities showed a net outflow of approximately 400.31 million in Q3 2022, compared to a net outflow of 659.89 million in Q3 2021, improving by about 39%[27]. - The company’s cash and cash equivalents stood at approximately $1.32 billion, slightly down from $1.34 billion[19]. - The cash and cash equivalents at the end of Q3 2022 amounted to approximately 1.10 billion, an increase from 710.12 million at the end of Q3 2021[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 52,006[9]. - The largest shareholder, Cheng Xianfeng, holds 40.50% of the shares, totaling 496,526,307 shares, with 66,500,000 shares pledged[9]. - The top ten shareholders hold a total of 124,131,577 unrestricted shares[12]. - Cheng Xianfeng's unrestricted shares amount to 124,131,577, while Hong Kong Central Clearing Limited holds 19,077,392 unrestricted shares[12]. - The company has not identified any other related party relationships among shareholders beyond those disclosed[13]. Government Support and Investments - The company received government subsidies amounting to ¥80,146,605.63 year-to-date, which is an increase of 134.61% compared to the previous year[8]. - Evive Biotech Ltd. plans to issue common stock at $7.2225 per share, with Sino Biopharmaceutical Limited investing $20 million for 2,769,132 shares and committing to invest at least $10 million in future financing[18]. - The total investment from Yifan Pharmaceutical (Hong Kong) Co., Ltd. amounts to $50 million for 6,922,831 shares, bringing the total investment in Evive to $70 million[18]. Operational Changes - The company’s long-term borrowings increased by 40.94% to ¥1,029,599,250.26 due to adjustments in financing structure[7]. - The company reported a 34.12% decrease in operating costs year-to-date, totaling ¥1,331,405,844.19, primarily due to reduced promotional service costs[8]. - The company completed the registration capital change, reducing it from RMB 1,234,106,077 to RMB 1,226,024,827[17]. - The employee stock ownership plan raised RMB 78.5 million, with 70 participants, and purchased 3,960,900 shares at an average price of approximately RMB 10.192 per share[15]. - The company has implemented a stock repurchase plan for restricted stock from 2019, with completion reported on July 29, 2022[14]. Regulatory Approvals - The company’s subsidiary received a drug registration certificate for lactulose oral solution on August 17, 2022[16]. - The company’s subsidiary obtained a registration approval for traditional Chinese medicine from the Singapore Health Sciences Authority in September 2022[16].